# MacroGenics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/macrogenics

- Industry: Biotechnology
- Headquarters: Rockville, US
- Website: www.macrogenics.com
- Total disclosed funding: $117M
- Latest round: Series D (Jan 14, 2013)
- Investors on record: 25

## About

MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics to treat various cancers, aiming to address critical unmet medical needs in oncology.Founded in 2000 and headquartered in Rockville, US, MacroGenics specializes in innovative cancer therapies. The company has undergone strategic pivots to enhance its focus on oncology therapeutics. Its CEO, Scott Koenig, has a strong background in the biopharmaceutical industry. In October 2013, the company raised USD 80 mn in an IPO, marking a significant milestone in its funding history, with a total of 14 deals reported to date.MacroGenics develops monoclonal antibody-based therapeutics for cancer treatment, including Lorigerlimab, MGC026, MGC028, and MGD024. These products target specific mechanisms within the immune system to improve anti-tumor responses. Their offerings cater to healthcare providers and research institutions across North America, Europe, and select Asian markets, aiming to enhance cancer treatment outcomes.In the most recent fiscal year of 2024, MacroGenics reported a revenue of USD 149.96 mn, with an EBITDA of USD -103.04 mn. The company generates revenue through partnerships and collaborations, leveraging its proprietary technologies alongside licensing agreements that include upfront fees and ongoing royalties from its flagship products.MacroGenics plans to further develop its innovative therapeutics pipeline, with ongoing research into new products targeting specific cancer types. The company is strategically looking to expand its presence in Europe and Asia by 2025, utilizing the funds raised from its IPO in October 2013 to support these initiatives and enhance its research and development efforts.

## Funding rounds

- Series D, Jan 14, 2013 — Alta Partners, InterWest Partners, Presidio Partners, China Investment and Development Company, Nextech, Hunt BioVentures
- Series D, Sep 25, 2008, $25M — Alta Partners, InterWest Partners, OrbiMed Advisors, Ventures West Capital, RiverVest Ventures Partners, China Investment and Development Company, Alexandria Venture Investments, Red Abbey, Nextech, Arcus Ventures, TPG Biotech, Mitsubishi UFJ Capital, Eli Lilly and Company Limited, Innovis Investment Partners
- Series D, Jul 29, 2008, $13M — Alta Partners, InterWest Partners, Clarus Ventures, TPG Biotech
- Series C, May 17, 2006, $35M — Alta Partners, InterWest Partners, OrbiMed Advisors, Ventures West Capital, RiverVest Ventures Partners, CDPQ, Red Abbey, Mithras Capital Partners, MPM BioImpact, TPG Biotech, Biogen Idec New Ventures
- Series B, Oct 15, 2004, $31M — Alta Partners, InterWest Partners, OrbiMed Advisors, Covera Ventures, Red Abbey, Cogene Ventures, Vivo Capital, Mithras Capital Partners, Emerging Technology Partners, MPM BioImpact, TPG Biotech
- Series A, Sep 25, 2001, $9.5M — InterWest Partners, OrbiMed Advisors, MPM BioImpact
- Series A, Jun 1, 2001, $4M — InterWest Partners, OrbiMed Advisors, MPM BioImpact

## Investors

- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A, Series B, Series C, Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B, Series C, Series D
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B, Series C
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series B, Series C, Series D
- Covera Ventures (https://capitalatlas.ai/funds/covera-ventures) — Series B
- Red Abbey (https://capitalatlas.ai/funds/red-abbey) — Series B, Series C, Series D
- Cogene Ventures (https://capitalatlas.ai/funds/cogene-ventures) — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- Mithras Capital Partners (https://capitalatlas.ai/funds/mithras-capital-partners) — Series B, Series C
- Emerging Technology Partners (https://capitalatlas.ai/funds/emerging-technology-partners) — Series B
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series B, Series C, Series D
- Ventures West Capital (https://capitalatlas.ai/funds/ventures-west-capital) — Series C, Series D
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series C, Series D
- CDPQ — Series C
- Biogen Idec New Ventures (https://capitalatlas.ai/funds/biogen-idec-new-ventures) — Series C
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series D
- China Investment and Development Company (https://capitalatlas.ai/funds/china-investment-and-development-company) — Series D
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series D
- Nextech (https://capitalatlas.ai/funds/nextech) — Series D
- Arcus Ventures (https://capitalatlas.ai/funds/arcus-ventures) — Series D
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series D
- Eli Lilly and Company Limited — Series D
- Innovis Investment Partners — Series D
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series D
- Hunt BioVentures (https://capitalatlas.ai/funds/hunt-bioventures) — Series D